Literature DB >> 11887863

Aspirin protected the nitric oxide/cyclic GMP generating system in human peritoneum.

M M Arriero1, A Celdran, P Jimenez, A García-Mendez, J C de la Pinta, F Manzarbeitia, L Muñoz-Alameda, A Reyero, M Escribano, S Casado, A López-Farré.   

Abstract

OBJECTIVE: Changes in the expression of endothelial nitric oxide synthase (eNOS) in the peritoneum could be involved in the peritoneal dysfunction associated with peritoneal inflammation. The aim of the present study was to analyze the effect of Escherichia coli lipopolysaccharide (LPS) on eNOS expression in samples of human peritoneum. The effect of aspirin, a drug with anti-inflammatory properties, was also determined.
RESULTS: The eNOS protein expressed in human peritoneal tissue was reduced by LPS (10 microg/mL) in a time-dependent manner. The eNOS was expressed mainly in capillary endothelial cells and mesothelial cells. Anti-inflammatory doses of aspirin (1-10 mmol/L) restored eNOS expression in LPS-stimulated human peritoneal tissue samples. The main intracellular receptor of NO, soluble guanylate cyclase (sGC), was also downregulated by LPS. This effect was prevented by aspirin (5 mmol/L).
CONCLUSION: Protein expression of the eNOS-sGC system in the peritoneal tissue was downregulated by LPS. High doses of aspirin protected both eNOS protein expression and sGC in human peritoneum. These findings suggest a new mechanism of action of aspirin that could be involved in the prevention of peritoneal dysfunction during inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11887863

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  1 in total

1.  Endothelial nitric oxide synthase/soluble guanylate cyclase system in human nasal polyps.

Authors:  Paloma Escobar; Francisco J Márquez; Carolina Carrasco; Sergio Alonso-Orgaz; José Fortes; Carlos Cenjor; Antonio López-Farré
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-11-18       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.